Identification
NamePioglitazone
Accession NumberDB01132  (APRD00653)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Pioglitazone is a medication belonging to the thiazolidinedione class of drugs that are used as adjuncts to diet, exercise, and other diabetes medications to manage type 2 diabetes mellitus. The thiazolidinedione class of medications exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose. Following entry into fat cell nuclei, pioglitazone selectively binds to the Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)[4]. PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes, and affect numerous metabolic processes, notably lipid and glucose homeostasis [5]. PPARγ in particular is abundantly expressed in lipid cells (adipocytes), where it plays a central role in lipid production and regulation of lipid metabolism.

Structure
Thumb
Synonyms
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
Pioglitazona
Pioglitazone
Pioglitazonum
External IDs U 72107A / U-72107A / U72107A
Product Ingredients
IngredientUNIICASInChI KeyDetails
Pioglitazone HydrochlorideJQT35NPK6C 112529-15-4GHUUBYQTCDQWRA-UHFFFAOYNA-NDetails
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel PioglitazoneTablet45 mgOralAccel Pharma Inc2009-06-02Not applicableCanada
Accel PioglitazoneTablet15 mgOralAccel Pharma Inc2009-06-02Not applicableCanada
Accel PioglitazoneTablet30 mgOralAccel Pharma Inc2009-06-02Not applicableCanada
Ach-pioglitazoneTablet30 mgOralAccord Healthcare Limited2010-06-11Not applicableCanada
Ach-pioglitazoneTablet15 mgOralAccord Healthcare Limited2012-10-12Not applicableCanada
Ach-pioglitazoneTablet45 mgOralAccord Healthcare Limited2010-06-11Not applicableCanada
Act PioglitazoneTablet30 mgOralActavis Pharma Company2007-12-05Not applicableCanada
Act PioglitazoneTablet45 mgOralActavis Pharma Company2007-12-05Not applicableCanada
Act PioglitazoneTablet15 mgOralActavis Pharma Company2007-12-05Not applicableCanada
ActosTablet45 mg/1OralPhysicians Total Care, Inc.2009-10-22Not applicableUs
ActosTablet30 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet45 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet15 mg/1OralRemedy Repack2013-04-022017-04-14Us
ActosTablet30 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet15 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet45 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet45 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet15 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet15 mg/1Occlusive dressing techniqueDispensing Solutions, Inc.1999-07-15Not applicableUs
ActosTablet30 mg/1OralPhysicians Total Care, Inc.2005-03-04Not applicableUs
ActosTablet15 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet30 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet45 mg/1OralTakeda1999-07-15Not applicableUs
ActosTablet45 mg/1OralCardinal Health1999-07-15Not applicableUs
ActosTablet15 mg/1OralRebel Distributors1999-07-15Not applicableUs
ActosTablet15 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet30 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-02-17Not applicableUs
ActosTablet30 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet15 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet30 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet30 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet15 mg/1OralTakeda1999-07-15Not applicableUs
ActosTablet15 mg/1OralCardinal Health1999-07-15Not applicableUs
ActosTablet45 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet45 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet15 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet30 mg/1OralRebel Distributors1999-07-15Not applicableUs
ActosTablet15 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet45 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet15 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet45 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-02-17Not applicableUs
ActosTablet30 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet15 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet45 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet15 mg/1OralPhysicians Total Care, Inc.2007-11-20Not applicableUs
ActosTablet30 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet30 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet30 mg/1OralTakeda1999-07-15Not applicableUs
ActosTablet30 mg/1OralCardinal Health1999-07-15Not applicableUs
ActosTablet45 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet45 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet30 mg/1Occlusive dressing techniqueDispensing Solutions, Inc.1999-07-15Not applicableUs
ActosTablet15 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-02-17Not applicableUs
ActosTablet15 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet45 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
ActosTablet30 mgOralTakeda Pharma A/S2000-10-13Not applicableEu
Actos (15mg)Tablet15 mgOralTakeda2000-08-28Not applicableCanada
Actos (30mg)Tablet30 mgOralTakeda2000-08-28Not applicableCanada
Actos (45mg)Tablet45 mgOralTakeda2000-08-28Not applicableCanada
Ag-pioglitazoneTablet45 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-pioglitazoneTablet30 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Auro-pioglitazoneTablet45 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-pioglitazoneTablet15 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-pioglitazoneTablet30 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Ava-pioglitazoneTablet30 mgOralAvanstra Inc2011-09-192014-08-21Canada
Ava-pioglitazoneTablet15 mgOralAvanstra Inc2011-10-242014-08-21Canada
Ava-pioglitazoneTablet45 mgOralAvanstra Inc2011-09-192014-08-21Canada
Dom-pioglitazoneTablet45 mgOralDominion Pharmacal2010-01-13Not applicableCanada
Dom-pioglitazoneTablet15 mgOralDominion Pharmacal2010-01-13Not applicableCanada
Dom-pioglitazoneTablet30 mgOralDominion Pharmacal2010-01-13Not applicableCanada
GlustinTablet45 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet45 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet30 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet30 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet45 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet45 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet15 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet45 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet30 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet15 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet45 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet15 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet15 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet30 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet15 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet15 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet30 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet30 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet30 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet45 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet45 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet30 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet15 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
GlustinTablet15 mgOralTakeda Pharma A/S2000-10-11Not applicableEu
Jamp-pioglitazoneTablet45 mgOralJamp Pharma Corporation2011-06-09Not applicableCanada
Jamp-pioglitazoneTablet30 mgOralJamp Pharma Corporation2011-06-09Not applicableCanada
Jamp-pioglitazoneTablet15 mgOralJamp Pharma Corporation2014-12-12Not applicableCanada
Mint-pioglitazoneTablet45 mgOralMint Pharmaceuticals Inc2009-07-21Not applicableCanada
Mint-pioglitazoneTablet15 mgOralMint Pharmaceuticals Inc2009-07-21Not applicableCanada
Mint-pioglitazoneTablet30 mgOralMint Pharmaceuticals Inc2009-07-21Not applicableCanada
Mylan-pioglitazoneTablet15 mgOralMylan Pharmaceuticals2007-12-05Not applicableCanada
Mylan-pioglitazoneTablet30 mgOralMylan Pharmaceuticals2007-12-05Not applicableCanada
Mylan-pioglitazoneTablet45 mgOralMylan Pharmaceuticals2007-12-05Not applicableCanada
PHL-pioglitazoneTablet15 mgOralPharmel Inc2009-08-28Not applicableCanada
PHL-pioglitazoneTablet30 mgOralPharmel Inc2009-08-28Not applicableCanada
PHL-pioglitazoneTablet45 mgOralPharmel Inc2009-08-28Not applicableCanada
PioglitazoneTablet45 mg/1OralTeva2012-08-17Not applicableUs00093 2046 56 nlmimage10 ee29773b
PioglitazoneTablet15 mgOralMeliapharm Inc2011-05-062014-06-25Canada
PioglitazoneTablet15 mg/1OralCarilion Materials Management2012-08-17Not applicableUs00093 2048 56 nlmimage10 632b3189
PioglitazoneTablet30 mg/1OralInternational Laboratories, Llc2013-12-08Not applicableUs
PioglitazoneTablet30 mgOralAccel Pharma IncNot applicableNot applicableCanada
PioglitazoneTablet45 mg/1OralRanbaxy Inc.2012-08-17Not applicableUs
PioglitazoneTablet30 mg/1OralTeva2012-08-17Not applicableUs00093 2047 56 nlmimage10 ea29752b
PioglitazoneTablet30 mgOralMeliapharm Inc2011-05-062014-06-25Canada
PioglitazoneTablet30 mg/1OralCarilion Materials Management2012-08-17Not applicableUs
PioglitazoneTablet45 mg/1OralInternational Laboratories, Inc.2013-12-082017-05-26Us
PioglitazoneTablet15 mg/1OralInternational Laboratories, Llc2013-12-08Not applicableUs
PioglitazoneTablet15 mg/1OralRanbaxy Inc.2012-08-17Not applicableUs
PioglitazoneTablet45 mgOralAccel Pharma IncNot applicableNot applicableCanada
PioglitazoneTablet15 mg/1OralMed Vantx, Inc.2012-08-17Not applicableUs
PioglitazoneTablet30 mg/1OralNu Care Pharmaceuticals,inc.2012-08-17Not applicableUs
PioglitazoneTablet15 mg/1OralTeva2012-08-17Not applicableUs
PioglitazoneTablet45 mgOralMeliapharm Inc2011-05-062014-06-25Canada
PioglitazoneTablet15 mgOralAccel Pharma IncNot applicableNot applicableCanada
PioglitazoneTablet30 mg/1OralRanbaxy Inc.2012-08-17Not applicableUs
Pioglitazone HClTablet15 mgOralSivem Pharmaceuticals Ulc2012-04-232015-01-12Canada
Pioglitazone HClTablet30 mgOralSivem Pharmaceuticals Ulc2012-04-23Not applicableCanada
Pioglitazone HClTablet45 mgOralSivem Pharmaceuticals Ulc2012-04-232015-01-12Canada
Pioglitazone HydrochlorideTablet15 mg/1OralAmerincan Health Packaging2013-06-252015-12-29Us
Pioglitazone HydrochlorideTablet30 mg/1OralAmerincan Health Packaging2013-06-252015-12-29Us
Pioglitazone HydrochlorideTablet45 mg/1OralAmerincan Health Packaging2013-06-252015-12-29Us
PMS-pioglitazoneTablet15 mgOralPharmascience Inc2007-12-05Not applicableCanada
PMS-pioglitazoneTablet30 mgOralPharmascience Inc2007-12-05Not applicableCanada
PMS-pioglitazoneTablet45 mgOralPharmascience Inc2007-12-05Not applicableCanada
Pro-pioglitazoneTablet15 mgOralPro Doc Limitee2008-10-27Not applicableCanada
Pro-pioglitazoneTablet30 mgOralPro Doc Limitee2008-10-27Not applicableCanada
Pro-pioglitazoneTablet45 mgOralPro Doc Limitee2008-10-27Not applicableCanada
Ran-pioglitazoneTablet30 mgOralRanbaxy Inc.2012-04-30Not applicableCanada
Ran-pioglitazoneTablet15 mgOralRanbaxy Inc.2012-04-30Not applicableCanada
Ran-pioglitazoneTablet45 mgOralRanbaxy Inc.2012-04-30Not applicableCanada
Ran-pioglitazoneTablet45 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Ratio-pioglitazoneTablet30 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-12-052015-10-26Canada
Ratio-pioglitazoneTablet15 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-12-052015-10-26Canada
Ratio-pioglitazoneTablet45 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-12-052015-10-26Canada
Sandoz PioglitazoneTablet45 mgOralSandoz Canada Incorporated2007-12-05Not applicableCanada
Sandoz PioglitazoneTablet15 mgOralSandoz Canada Incorporated2007-12-05Not applicableCanada
Sandoz PioglitazoneTablet30 mgOralSandoz Canada Incorporated2007-12-05Not applicableCanada
Teva-pioglitazoneTablet45 mgOralTeva2007-12-05Not applicableCanada
Teva-pioglitazoneTablet15 mgOralTeva2007-12-05Not applicableCanada
Teva-pioglitazoneTablet30 mgOralTeva2007-12-05Not applicableCanada
Torrent-pioglitazoneTablet15 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-pioglitazoneTablet30 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-pioglitazoneTablet45 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Van-pioglitazoneTablet15 mgOralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-pioglitazoneTablet30 mgOralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-pioglitazoneTablet45 mgOralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Zym-pioglitazoneTablet30 mgOralZymcan Pharmaceuticals Inc2009-12-292014-06-16Canada
Zym-pioglitazoneTablet45 mgOralZymcan Pharmaceuticals Inc2009-12-292014-06-16Canada
Zym-pioglitazoneTablet15 mgOralZymcan Pharmaceuticals Inc2009-12-292014-06-16Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-pioglitazoneTablet30 mgOralApotex Corporation2007-12-05Not applicableCanada
Apo-pioglitazoneTablet45 mgOralApotex Corporation2007-12-05Not applicableCanada
Apo-pioglitazoneTablet15 mgOralApotex Corporation2007-12-05Not applicableCanada
GlidipionTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
GlidipionTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
PioglitazoneTablet30 mg/1OralZydus Pharmaceuticals Usa, Inc.2016-11-16Not applicableUs
PioglitazoneTablet15 mg/1OralMacleods Pharmaceuticals Limited2013-02-14Not applicableUs
PioglitazoneTablet15 mg/1OralAvera Mc Kennan Hospital2016-02-15Not applicableUs
PioglitazoneTablet30 mg/1OralWockhardt2013-02-13Not applicableUs
PioglitazoneTablet15 mg/1OralAmerincan Health Packaging2014-01-222016-02-29Us
PioglitazoneTablet45 mg/1OralWockhardt2013-02-13Not applicableUs
PioglitazoneTablet45 mg/1OralCitron Pharma LLC2013-02-13Not applicableUs
PioglitazoneTablet30 mg/1OralCadila Pharnmaceuticals2016-11-16Not applicableUs
PioglitazoneTablet45 mg/1OralSandoz2013-03-01Not applicableUs
PioglitazoneTablet15 mg/1OralRanbaxy Inc.2013-02-072016-01-21Us
PioglitazoneTablet15 mg/1OralZydus Pharmaceuticals Usa, Inc.2016-11-16Not applicableUs
PioglitazoneTablet30 mg/1OralAmerincan Health Packaging2014-01-222015-12-31Us
PioglitazoneTablet45 mg/1OralTeva2015-01-01Not applicableUs00093 7273 98 nlmimage10 4f4727a9
PioglitazoneTablet15 mg/1OralMylan Institutional2012-09-06Not applicableUs
PioglitazoneTablet15 mg/1OralAvera Mc Kennan Hospital2016-06-28Not applicableUs
PioglitazoneTablet15 mg/1OralInternational Laboratories, Llc2015-05-01Not applicableUs00093 7271 98 nlmimage10 b543da9e
PioglitazoneTablet45 mg/1OralMylan Pharmaceuticals2012-08-17Not applicableUs
PioglitazoneTablet15 mg/1OralCitron Pharma LLC2013-02-13Not applicableUs
PioglitazoneTablet45 mg/1OralZydus Pharmaceuticals Usa, Inc.2016-11-16Not applicableUs
PioglitazoneTablet30 mg/1OralMacleods Pharmaceuticals Limited2013-02-14Not applicableUs33342 0055 10 nlmimage10 d9496ceb
PioglitazoneTablet15 mg/1OralSandoz2013-03-01Not applicableUs
PioglitazoneTablet30 mg/1OralA S Medication Solutions2015-02-042017-06-20Us
PioglitazoneTablet15 mg/1OralTeva2015-01-01Not applicableUs
PioglitazoneTablet45 mg/1OralWockhardt2013-02-13Not applicableUs
PioglitazoneTablet15 mg/1OralWockhardt2013-02-13Not applicableUs
PioglitazoneTablet30 mg/1OralMylan Institutional2012-09-06Not applicableUs
PioglitazoneTablet15 mg/1OralMylan Pharmaceuticals2012-08-17Not applicableUs
PioglitazoneTablet45 mg/1OralCadila Pharnmaceuticals2016-11-16Not applicableUs
PioglitazoneTablet45 mg/1OralInternational Laboratories, Llc2015-05-01Not applicableUs
PioglitazoneTablet30 mg/1OralRanbaxy Inc.2013-02-072016-01-21Us
PioglitazoneTablet45 mg/1OralAmerincan Health Packaging2014-01-222015-12-31Us
PioglitazoneTablet15 mg/1OralClinical Solutions Wholsesale2013-03-012017-06-24Us
PioglitazoneTablet15 mg/1OralWockhardt2013-02-13Not applicableUs
PioglitazoneTablet30 mg/1OralWockhardt2013-02-13Not applicableUs
PioglitazoneTablet30 mg/1OralCitron Pharma LLC2013-02-13Not applicableUs
PioglitazoneTablet15 mg/1OralCadila Pharnmaceuticals2016-11-16Not applicableUs
PioglitazoneTablet45 mg/1OralMacleods Pharmaceuticals Limited2013-02-14Not applicableUs
PioglitazoneTablet30 mg/1OralSandoz2013-03-01Not applicableUs
PioglitazoneTablet45 mg/1OralA S Medication Solutions2015-05-222017-06-20Us
PioglitazoneTablet30 mg/1OralTeva2015-01-01Not applicableUs
PioglitazoneTablet45 mg/1OralRanbaxy Inc.2013-02-072016-01-21Us
PioglitazoneTablet45 mg/1OralMylan Institutional2012-09-06Not applicableUs
PioglitazoneTablet30 mg/1OralMylan Pharmaceuticals2012-08-17Not applicableUs
PioglitazoneTablet45 mg/1OralA S Medication Solutions2013-02-142017-06-20Us
PioglitazoneTablet30 mg/1OralInternational Laboratories, Llc2015-05-01Not applicableUs00093 7272 05 nlmimage10 a542d2f6
Pioglitazone AccordTablet15 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet30 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet15 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet30 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet45 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet15 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet30 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet30 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet45 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet15 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet30 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet45 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet15 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet45 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet15 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet30 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet45 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet30 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet45 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet15 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet30 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet45 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet45 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet15 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet45 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet15 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet30 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet15 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet30 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone AccordTablet45 mgOralAccord Healthcare Limited2012-03-21Not applicableEu
Pioglitazone ActavisTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet30 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet15 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone ActavisTablet45 mgOralActavis Group Ptc Ehf.2012-03-15Not applicableEu
Pioglitazone HydrochlorideTablet30 mg/1OralAccord Healthcare Limited2013-02-13Not applicableUs16729 0021 16 nlmimage10 60413019
Pioglitazone HydrochlorideTablet30 mg/1OralRemedy Repack2016-01-25Not applicableUs
Pioglitazone HydrochlorideTablet15 mg/1OralGolden State Medical Supply2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet15 mg/1OralAmerincan Health Packaging2013-06-202015-12-30Us
Pioglitazone HydrochlorideTablet45 mg/1OralAurobindo Pharma2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet15 mg/1OralActavis Pharma Company2012-10-26Not applicableUs
Pioglitazone HydrochlorideTablet30 mg/1OralNu Care Pharmaceuticals,inc.2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet15 mg/1OralLucid Pharma Llc2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet45 mg/1OralBreckenridge Pharmaceutical, Inc.2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet15 mg/1OralAccord Healthcare Limited2013-02-13Not applicableUs16729 0020 15 nlmimage10 093f84dc
Pioglitazone HydrochlorideTablet45 mg/1OralPreferreed Pharmaceuticals Inc.2017-02-01Not applicableUs
Pioglitazone HydrochlorideTablet45 mg/1Oralbryant ranch prepack2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet15 mg/1OralAurobindo Pharma2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet15 mg/1Oralbryant ranch prepack2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet15 mg/1OralBreckenridge Pharmaceutical, Inc.2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet15 mg/1OralA S Medication Solutions2013-02-132017-06-20Us
Pioglitazone HydrochlorideTablet45 mg/1OralAccord Healthcare Limited2013-02-13Not applicableUs16729 0022 15 nlmimage10 65413289
Pioglitazone HydrochlorideTablet45 mg/1OralA S Medication Solutions2013-02-132017-06-20Us
Pioglitazone HydrochlorideTablet30 mg/1OralGolden State Medical Supply2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet30 mg/1OralAmerincan Health Packaging2013-06-202015-12-30Us
Pioglitazone HydrochlorideTablet30 mg/1OralActavis Pharma Company2012-10-26Not applicableUs
Pioglitazone HydrochlorideTablet45 mg/1OralA S Medication Solutions2012-10-262017-06-20Us
Pioglitazone HydrochlorideTablet30 mg/1OralNu Care Pharmaceuticals,inc.2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet30 mg/1OralLucid Pharma Llc2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet15 mg/1OralPreferreed Pharmaceuticals Inc.2016-06-14Not applicableUs
Pioglitazone HydrochlorideTablet15 mg/1OralNucare Pharmaceuticals, Inc.2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet30 mg/1OralA S Medication Solutions2013-02-132017-06-20Us
Pioglitazone HydrochlorideTablet30 mg/1OralAurobindo Pharma2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet15 mg/1OralAmerincan Health Packaging2015-04-15Not applicableUs
Pioglitazone HydrochlorideTablet30 mg/1OralBreckenridge Pharmaceutical, Inc.2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet45 mg/1OralLucid Pharma Llc2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet45 mg/1OralGolden State Medical Supply2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet45 mg/1OralAmerincan Health Packaging2013-06-202015-12-30Us
Pioglitazone HydrochlorideTablet45 mg/1OralActavis Pharma Company2012-10-26Not applicableUs
Pioglitazone HydrochlorideTablet15 mg/1OralRemedy Repack2016-01-25Not applicableUs
Pioglitazone HydrochlorideTablet30 mg/1Oralbryant ranch prepack2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet15 mg/1OralDispensing Solutions, Inc.2013-02-13Not applicableUs
Pioglitazone HydrochlorideTablet30 mg/1OralPreferreed Pharmaceuticals Inc.2016-06-14Not applicableUs
Pioglitazone HydrochlorideTablet30 mg/1OralPreferreed Pharmaceuticals Inc.2016-12-07Not applicableUs
Pioglitazone TevaTablet30 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet45 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet15 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet30 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet15 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet30 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet45 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet15 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet45 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet15 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet30 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet45 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet15 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet30 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet30 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet45 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet15 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet30 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet45 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet15 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet30 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet45 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet15 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet45 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet15 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet30 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet45 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet15 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet30 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone TevaTablet45 mgOralTeva B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet30 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet45 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet15 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet30 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet45 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet15 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet15 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet30 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet45 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet15 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet30 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet45 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet30 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet45 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet45 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet15 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet30 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet45 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet15 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet30 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet15 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet45 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet30 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet45 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet15 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet30 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet30 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet15 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet30 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet45 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet15 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
Pioglitazone Teva PharmaTablet45 mgOralTeva Pharma B.V.2012-03-26Not applicableEu
PioglitazonehydrochlorideTablet30 mg/1OralProficient Rx LP2013-02-13Not applicableUs
PioglitazonehydrochlorideTablet15 mg/1OralTorrent Pharmaceuticals Limited2013-02-13Not applicableUs13668 0140 05 nlmimage10 023e8104
PioglitazonehydrochlorideTablet15 mg/1OralA S Medication Solutions2013-02-132017-06-20Us
PioglitazonehydrochlorideTablet30 mg/1OralA S Medication Solutions2013-02-132017-06-20Us
PioglitazonehydrochlorideTablet30 mg/1OralTorrent Pharmaceuticals Limited2013-02-13Not applicableUs
PioglitazonehydrochlorideTablet45 mg/1OralTorrent Pharmaceuticals Limited2013-02-13Not applicableUs
PioglitazonehydrochlorideTablet45 mg/1OralA S Medication Solutions2013-02-132017-06-20Us
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PaglitazTablet15 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet30 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet30 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet45 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet15 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet45 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet30 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet15 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet45 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet15 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet30 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet30 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet15 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet45 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet30 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet45 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet15 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet45 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet30 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet45 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
PaglitazTablet15 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet45 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet15 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet30 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet15 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet45 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet45 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet15 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet30 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet45 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet15 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet15 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet30 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet30 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet45 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet30 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet30 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet45 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet15 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet15 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet45 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
Pioglitazone KrkaTablet30 mgOralKrka, D.D., Novo Mesto2012-03-21Not applicableEu
SepioglinTablet15 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet45 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet45 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet15 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet45 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet15 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet30 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet30 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet15 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet30 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet45 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet45 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet15 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet30 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet30 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet15 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet15 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet30 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet45 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet45 mgOralVaia S.A.2012-03-09Not applicableEu
SepioglinTablet30 mgOralVaia S.A.2012-03-09Not applicableEu
International Brands
NameCompany
ActostNot Available
GlustinNot Available
Brand mixtures
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Actoplus MetTablet, film coatedOralPhysicians Total Care, Inc.2006-01-04Not applicableUs
Actoplus Met XRTablet, film coated, extended releaseOralTakeda2010-06-11Not applicableUs
Alogliptin and PioglitazoneTablet, film coatedOralPerrigo New York Inc.2016-04-08Not applicableUs
DuetactTabletOralTakeda2006-07-28Not applicableUs
GlubravaTablet, film coatedOralTakeda Pharma A/S2007-12-11Not applicableEu
IncresyncTablet, film coatedOralTakeda Pharma A/S2013-09-19Not applicableEu
OseniTabletOralTakedaNot applicableNot applicableCanada
Pioglitazole and metformin hydrochlorideTabletOralMacleods Pharmaceuticals Limited2015-11-06Not applicableUs
Pioglitazone and GlimepirideTabletOralPrasco, Laboratories2015-08-04Not applicableUs
Pioglitazone and metforminTablet, film coatedOralSandoz2013-05-02Not applicableUs00781 5626 60 nlmimage10 633eb1c5
Pioglitazone and Metformin HydrochlorideTablet, film coatedOralAv Kare, Inc.2015-03-06Not applicableUs00093 7677 86 nlmimage10 5643ab5d
Pioglitazone and Metformin HydrocholrideTablet, film coatedOralTeva2012-08-17Not applicableUs00093 5049 06 nlmimage10 a22d511a
Pioglitazone HCL and Metformin HCLTabletOralTorrent Pharmaceuticals Limited2013-02-13Not applicableUs13668 0280 60 nlmimage10 7d413eb9
Pioglitazone hydrochloride and glimepirideTabletOralSandoz2013-01-08Not applicableUs
Pioglitazone Hydrochloride and Metformin HydrochlorideTablet, film coatedOralAurobindo Pharma2013-02-13Not applicableUs
TandemactTabletOralTakeda Pharma A/S2007-01-08Not applicableEu
Categories
UNIIX4OV71U42S
CAS number111025-46-8
WeightAverage: 356.439
Monoisotopic: 356.119463206
Chemical FormulaC19H20N2O3S
InChI KeyHYAFETHFCAUJAY-UHFFFAOYSA-N
InChI
InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)
IUPAC Name
5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione
SMILES
CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Pharmacology
Indication

Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [FDA Label].

Structured Indications
Pharmacodynamics

Pioglitazone enhances cellular responsiveness to insulin, increases insulin-dependent glucose disposal and improves hepatic sensitivity to insulin. In patients with type 2 diabetes, the decreased insulin resistance produced by pioglitazone results in lower plasma glucose concentrations, lower plasma insulin concentrations, and lower HbA1c values [FDA Label]

Additionally, patients treated with pioglitazone had mean decreases in serum triglycerides, mean increases in HDL cholesterol, and no consistent mean changes in LDL and total cholesterol [FDA Label].

Mechanism of action

Pioglitazone acts as a selective agonist at Peroxisome Proliferator Activated Receptor Gamma (PPARγ) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors increases the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, pioglitazone both enhances tissue sensitivity to insulin and reduces the production of glucose via the liver (hepatic gluconeogenesis). Thus, insulin resistance associated with type 2 diabetes mellitus is improved without an increase in insulin secretion by pancreatic β cells.

TargetKindPharmacological actionActionsOrganismUniProt ID
Peroxisome proliferator-activated receptor gammaProteinyes
agonist
HumanP37231 details
Peroxisome proliferator-activated receptor deltaProteinunknownNot AvailableHumanQ03181 details
Peroxisome proliferator-activated receptor alphaProteinunknownNot AvailableHumanQ07869 details
Amine oxidase [flavin-containing] BProteinunknownNot AvailableHumanP27338 details
Related Articles
Absorption

Following oral administration of pioglitazone, peak concentrations of pioglitazone were observed within 2 hours. Food slightly delays the time to peak serum concentration (T max) to 3 to 4 hours, but does not alter the extent of absorption (AUC). Steady state concentrations are achieved after 7 days of once daily administration of pioglitazone [FDA Label].

Volume of distribution

0.63 ± 0.41 L/kg [FDA Label]

Protein binding

Pioglitazone is extensively protein bound (> 99%) in human serum, principally to serum albumin. Pioglitazone also binds to other serum proteins, but with lower affinity [FDA Label].

Metabolism

Pioglitazone is extensively metabolized by hydroxylation and oxidation; the metabolites also partly convert to glucuronide or sulfate conjugates. Metabolites M-III and M-IV are the major circulating active metabolites in humans. The cytochrome P450 isoforms involved are CYP2C8 and, to a lesser degree, CYP3A4 with additional contributions from a variety of other isoforms including the mainly extrahepatic CYP1A1 [FDA Label].

SubstrateEnzymesProduct
Pioglitazone
Not Available
Pioglitazone metabolite M-IDetails
Pioglitazone
Pioglitazone metabolite M-IIDetails
Pioglitazone metabolite M-II
Not Available
Pioglitazone metabolite M-II metaboliteDetails
Pioglitazone metabolite M-II
Pioglitazone metabolite M-XIDetails
Pioglitazone
Pioglitazone metabolite M-VIDetails
Pioglitazone
Pioglitazone metabolite M-VDetails
Pioglitazone metabolite M-V
Not Available
Pioglitazone metabolite M-VIDetails
Pioglitazone
Pioglitazone metabolite M-IVDetails
Pioglitazone metabolite M-IV
Not Available
Pioglitazone metabolite M-IIIDetails
Pioglitazone metabolite M-IV
Pioglitazone metabolite M-XIDetails
Route of elimination

Following oral administration, approximately 15% to 30% of the pioglitazone dose is recovered in the urine. Renal elimination of pioglitazone is negligible, and the drug is excreted primarily as metabolites and their conjugates. It is presumed that most of the oral dose is excreted into the bile either unchanged or as metabolites and eliminated in the feces [FDA Label].

Half life

The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].

Clearance

The apparent clearance of orally administered pioglitazone is 5 - 7 L/h [FDA Label].

ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Pioglitazone.Experimental
AbirateroneThe serum concentration of Pioglitazone can be increased when it is combined with Abiraterone.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Pioglitazone.Approved
AcetohexamidePioglitazone may increase the hypoglycemic activities of Acetohexamide.Withdrawn
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Pioglitazone.Approved, Vet Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Pioglitazone.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Pioglitazone.Approved, Withdrawn
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Pioglitazone.Approved
AmiodaroneThe metabolism of Pioglitazone can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Pioglitazone.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Pioglitazone.Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Pioglitazone.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Pioglitazone.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Pioglitazone.Approved
AprepitantThe serum concentration of Pioglitazone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Pioglitazone.Approved, Investigational
Arsenic trioxideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Asenapine.Approved
AtazanavirThe metabolism of Pioglitazone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Pioglitazone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Pioglitazone.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Pioglitazone.Approved
BalsalazideBalsalazide may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Pioglitazone.Withdrawn
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Pioglitazone.Approved
BeraprostThe metabolism of Beraprost can be decreased when combined with Pioglitazone.Investigational
BetamethasoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BexaroteneThe serum concentration of Pioglitazone can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Pioglitazone can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Pioglitazone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Pioglitazone can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Brexpiprazole.Approved
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Pioglitazone.Approved
BumetanideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Bumetanide.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Pioglitazone.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Pioglitazone.Approved
BuserelinThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Buserelin.Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Pioglitazone.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Pioglitazone.Approved
CapecitabineThe metabolism of Pioglitazone can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Pioglitazone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Pioglitazone.Approved
CaroxazoneCaroxazone may increase the hypoglycemic activities of Pioglitazone.Withdrawn
CelecoxibThe metabolism of Pioglitazone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Pioglitazone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Pioglitazone.Withdrawn
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Pioglitazone.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpropamidePioglitazone may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Chlorthalidone.Approved
CholecalciferolThe metabolism of Pioglitazone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Pioglitazone.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Withdrawn
CiprofloxacinCiprofloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Pioglitazone.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the hypoglycemic activities of Pioglitazone.Approved
ClarithromycinThe metabolism of Pioglitazone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Pioglitazone can be decreased when combined with Clemastine.Approved
ClopidogrelThe serum concentration of Pioglitazone can be increased when it is combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Pioglitazone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Clozapine.Approved
CobicistatThe metabolism of Pioglitazone can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Pioglitazone can be increased when it is combined with Conivaptan.Approved, Investigational
CorticotropinThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Cortisone acetate.Approved
CrizotinibThe metabolism of Pioglitazone can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Pioglitazone.Approved, Investigational
CyclosporineThe metabolism of Pioglitazone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Pioglitazone can be decreased when it is combined with Dabrafenib.Approved
DanazolThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Danazol.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Pioglitazone.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Pioglitazone.Approved, Investigational
DarunavirThe metabolism of Pioglitazone can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Pioglitazone.Approved
DasatinibThe serum concentration of Pioglitazone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Pioglitazone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Pioglitazone can be decreased when combined with Delavirdine.Approved
dersalazinedersalazine may increase the hypoglycemic activities of Pioglitazone.Investigational
DesogestrelThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Pioglitazone.Approved
DexamethasoneThe serum concentration of Pioglitazone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Pioglitazone.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Pioglitazone.Approved, Illicit, Vet Approved
DiazoxideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Diazoxide.Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Pioglitazone.Approved, Vet Approved
DienogestThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Dienogest.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Pioglitazone.Approved
DihydroergotamineThe metabolism of Pioglitazone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Pioglitazone.Illicit
DiltiazemThe metabolism of Pioglitazone can be decreased when combined with Diltiazem.Approved
DisopyramidePioglitazone may increase the hypoglycemic activities of Disopyramide.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Pioglitazone.Approved, Investigational, Vet Approved
DoxycyclineThe metabolism of Pioglitazone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Pioglitazone can be decreased when combined with Dronedarone.Approved
DrospirenoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Drospirenone.Approved
DuloxetineDuloxetine may increase the hypoglycemic activities of Pioglitazone.Approved
EfavirenzThe serum concentration of Pioglitazone can be decreased when it is combined with Efavirenz.Approved, Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Pioglitazone.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Pioglitazone.Approved
EnzalutamideThe serum concentration of Pioglitazone can be decreased when it is combined with Enzalutamide.Approved
EpinephrineThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Epinephrine.Approved, Vet Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Pioglitazone.Approved, Investigational
ErythromycinThe metabolism of Pioglitazone can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Pioglitazone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Estrone sulfate.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Pioglitazone.Approved
Etacrynic acidThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Etacrynic acid.Approved
Ethinyl EstradiolThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethynodiol diacetateThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ethynodiol diacetate.Approved
EtonogestrelThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoperidoneEtoperidone may increase the hypoglycemic activities of Pioglitazone.Approved
EtravirineThe serum concentration of Pioglitazone can be decreased when it is combined with Etravirine.Approved
EverolimusThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Everolimus.Approved
FelodipineThe metabolism of Pioglitazone can be decreased when combined with Felodipine.Approved, Investigational
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pioglitazone.Approved
FleroxacinFleroxacin may increase the hypoglycemic activities of Pioglitazone.Approved
FloxuridineThe metabolism of Pioglitazone can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Pioglitazone can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Fludrocortisone.Approved
FlumequineFlumequine may increase the hypoglycemic activities of Pioglitazone.Withdrawn
FluorouracilThe metabolism of Pioglitazone can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the hypoglycemic activities of Pioglitazone.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Pioglitazone.Approved, Illicit
FluvastatinThe metabolism of Pioglitazone can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Pioglitazone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Pioglitazone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pioglitazone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Pioglitazone can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Pioglitazone.Approved, Vet Approved
FurosemideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Pioglitazone can be increased when it is combined with Fusidic Acid.Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Pioglitazone.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
GemfibrozilThe metabolism of Pioglitazone can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
GlibornuridePioglitazone may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazidePioglitazone may increase the hypoglycemic activities of Gliclazide.Approved
GlimepiridePioglitazone may increase the hypoglycemic activities of Glimepiride.Approved
GlipizidePioglitazone may increase the hypoglycemic activities of Glipizide.Approved
GliquidonePioglitazone may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepidePioglitazone may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburidePioglitazone may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Goserelin.Approved
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Pioglitazone.Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Pioglitazone.Approved
HistrelinThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Pioglitazone.Experimental
HydrochlorothiazideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Pioglitazone.Approved, Illicit
HydrocortisoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydroflumethiazide.Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Pioglitazone.Approved
IdelalisibThe serum concentration of Pioglitazone can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Pioglitazone.Approved
IloperidoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Iloperidone.Approved
ImatinibThe metabolism of Pioglitazone can be decreased when combined with Imatinib.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Pioglitazone.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Indapamide.Approved
IndinavirThe metabolism of Pioglitazone can be decreased when combined with Indinavir.Approved
Insulin AspartPioglitazone may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirPioglitazone may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlarginePioglitazone may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisinePioglitazone may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanPioglitazone may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproPioglitazone may increase the hypoglycemic activities of Insulin Lispro.Approved
Insulin PorkThe risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin Pork.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Pioglitazone.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Pioglitazone.Withdrawn
IrbesartanThe metabolism of Pioglitazone can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Pioglitazone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Pioglitazone.Approved
IsradipineThe metabolism of Pioglitazone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Pioglitazone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Pioglitazone can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Pioglitazone.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Pioglitazone.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Pioglitazone.Approved
KetoconazoleThe metabolism of Pioglitazone can be decreased when combined with Ketoconazole.Approved, Investigational
LanreotideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lanreotide.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Pioglitazone.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Pioglitazone.Approved, Investigational
LeflunomideThe metabolism of Pioglitazone can be decreased when combined with Leflunomide.Approved, Investigational
LeuprolideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Leuprolide.Approved, Investigational
LevofloxacinLevofloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Pioglitazone.Approved
LevonorgestrelThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Pioglitazone.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Pioglitazone.Approved, Vet Approved
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Pioglitazone.Approved, Nutraceutical
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Pioglitazone.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Pioglitazone.Approved
LopinavirThe serum concentration of Pioglitazone can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Pioglitazone.Approved
LosartanThe metabolism of Pioglitazone can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Pioglitazone can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Pioglitazone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pioglitazone can be increased when it is combined with Lumacaftor.Approved
LurasidoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lurasidone.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Pioglitazone.Withdrawn
MecaserminPioglitazone may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Medroxyprogesterone acetateThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Pioglitazone.Approved
Megestrol acetateThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Pioglitazone.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Pioglitazone.Investigational, Withdrawn
MesalazineMesalazine may increase the hypoglycemic activities of Pioglitazone.Approved
MestranolThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Mestranol.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Pioglitazone.Approved
MethotrimeprazineThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Pioglitazone.Investigational
MethylprednisoloneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Pioglitazone.Approved
MetolazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Pioglitazone.Approved, Investigational
MifepristoneThe serum concentration of Pioglitazone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the hypoglycemic activities of Pioglitazone.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Pioglitazone.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Pioglitazone.Approved
MitotaneThe serum concentration of Pioglitazone can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypoglycemic activities of Pioglitazone.Approved
ModafinilThe serum concentration of Pioglitazone can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe metabolism of Morphine can be decreased when combined with Pioglitazone.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Pioglitazone.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Pioglitazone.Approved, Investigational
NafcillinThe serum concentration of Pioglitazone can be decreased when it is combined with Nafcillin.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Pioglitazone.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Pioglitazone.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Pioglitazone.Approved, Vet Approved
NateglinidePioglitazone may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NefazodoneThe metabolism of Pioglitazone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Pioglitazone can be decreased when combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Pioglitazone.Investigational
NetupitantThe serum concentration of Pioglitazone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Pioglitazone can be increased when combined with Nevirapine.Approved
NiacinThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypoglycemic activities of Pioglitazone.Withdrawn
NicardipineThe metabolism of Pioglitazone can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Pioglitazone.Approved
NilotinibThe metabolism of Pioglitazone can be decreased when combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Pioglitazone.Approved
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Pioglitazone.Investigational
NorethisteroneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Pioglitazone.Approved
NorgestimateThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Norgestimate.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Pioglitazone.Withdrawn
OctreotideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Octreotide.Approved, Investigational
OfloxacinOfloxacin may increase the hypoglycemic activities of Pioglitazone.Approved
OlanzapineThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Pioglitazone can be decreased when combined with Olaparib.Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Pioglitazone.Approved
OlsalazineOlsalazine may increase the hypoglycemic activities of Pioglitazone.Approved
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Pioglitazone.Approved
OmeprazoleThe metabolism of Pioglitazone can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Pioglitazone can be increased when it is combined with Osimertinib.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
OxymetholoneOxymetholone may increase the hypoglycemic activities of Pioglitazone.Approved, Illicit
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Pioglitazone.Approved, Vet Approved
PalbociclibThe serum concentration of Pioglitazone can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Paliperidone.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Pioglitazone.Approved
PargylinePargyline may increase the hypoglycemic activities of Pioglitazone.Approved
ParoxetineParoxetine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PasireotideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Pasireotide.Approved
PazopanibThe metabolism of Pazopanib can be decreased when combined with Pioglitazone.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Pioglitazone.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Pioglitazone.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Pioglitazone.Approved
PentamidineThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Pentamidine.Approved
PentobarbitalThe metabolism of Pioglitazone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Pioglitazone.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Pioglitazone.Approved
PheniprazinePheniprazine may increase the hypoglycemic activities of Pioglitazone.Withdrawn
PhenobarbitalThe metabolism of Pioglitazone can be increased when combined with Phenobarbital.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Pioglitazone.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Pioglitazone.Approved
PhenytoinThe metabolism of Pioglitazone can be increased when combined with Phenytoin.Approved, Vet Approved
PiperazineThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Pipotiazine.Approved
PirlindolePirlindole may increase the hypoglycemic activities of Pioglitazone.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Pioglitazone.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Pioglitazone.Approved
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Pioglitazone.Withdrawn
PolythiazideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Polythiazide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Pioglitazone.Approved
PosaconazoleThe metabolism of Pioglitazone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrednisoloneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Prednisone.Approved, Vet Approved
PregabalinPregabalin may increase the fluid retaining activities of Pioglitazone.Approved, Illicit, Investigational
PrimidoneThe metabolism of Pioglitazone can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Progesterone.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Pioglitazone.Approved, Investigational, Vet Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Pioglitazone.Investigational
PyrimethamineThe metabolism of Pioglitazone can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Quinethazone.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Pioglitazone.Approved
QuinineThe metabolism of Pioglitazone can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Pioglitazone can be decreased when combined with Rabeprazole.Approved, Investigational
RanolazineThe metabolism of Pioglitazone can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Pioglitazone.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Pioglitazone.Approved, Investigational
RifabutinThe metabolism of Pioglitazone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Pioglitazone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Pioglitazone can be increased when combined with Rifapentine.Approved
RiociguatThe metabolism of Riociguat can be decreased when combined with Pioglitazone.Approved
RisperidoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe serum concentration of Pioglitazone can be increased when it is combined with Ritonavir.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Pioglitazone.Investigational, Withdrawn
RosiglitazoneThe metabolism of Pioglitazone can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Pioglitazone.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Pioglitazone.Withdrawn
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Pioglitazone.Approved, Vet Approved
SaquinavirThe metabolism of Pioglitazone can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Pioglitazone.Approved
SecobarbitalThe metabolism of Pioglitazone can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Pioglitazone.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Pioglitazone.Approved
SertralineSertraline may increase the hypoglycemic activities of Pioglitazone.Approved
SildenafilThe metabolism of Pioglitazone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Pioglitazone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Pioglitazone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Pioglitazone.Approved
SirolimusThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Sirolimus.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Pioglitazone.Approved, Investigational
SorafenibThe metabolism of Pioglitazone can be decreased when combined with Sorafenib.Approved, Investigational
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Pioglitazone.Approved
St. John's WortThe serum concentration of Pioglitazone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololStanozolol may increase the hypoglycemic activities of Pioglitazone.Approved, Vet Approved
StiripentolThe serum concentration of Pioglitazone can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Pioglitazone can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Pioglitazone can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Pioglitazone.Approved
SulfisoxazoleThe metabolism of Pioglitazone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibPioglitazone may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Tacrolimus.Approved, Investigational
TamoxifenThe metabolism of Pioglitazone can be decreased when combined with Tamoxifen.Approved
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Pioglitazone.Approved, Investigational
TelaprevirThe metabolism of Pioglitazone can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Pioglitazone can be decreased when combined with Telithromycin.Approved
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Pioglitazone.Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Pioglitazone.Approved
TemsirolimusThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Temsirolimus.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Pioglitazone.Approved, Investigational, Vet Approved
TeriflunomideThe metabolism of Pioglitazone can be decreased when combined with Teriflunomide.Approved
TestosteroneThe metabolism of Testosterone can be decreased when combined with Pioglitazone.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Pioglitazone.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Pioglitazone.Withdrawn
TicagrelorThe metabolism of Pioglitazone can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Pioglitazone can be decreased when combined with Ticlopidine.Approved
TipranavirThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Pioglitazone can be decreased when it is combined with Tocilizumab.Approved
TolazamidePioglitazone may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamidePioglitazone may increase the hypoglycemic activities of Tolbutamide.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Pioglitazone.Approved
TorasemideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Torasemide.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Pioglitazone.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Pioglitazone.Approved
TretinoinThe metabolism of Tretinoin can be decreased when combined with Pioglitazone.Approved, Investigational, Nutraceutical
TriamcinoloneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Pioglitazone.Approved
TrimethoprimThe metabolism of Pioglitazone can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Pioglitazone.Withdrawn
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Withdrawn
Valproic AcidThe metabolism of Pioglitazone can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Pioglitazone can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Pioglitazone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Pioglitazone can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Pioglitazone can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Vorinostat.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Pioglitazone.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Pioglitazone.Approved
ZafirlukastThe metabolism of Pioglitazone can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Pioglitazone.Approved
ZimelidineZimelidine may increase the hypoglycemic activities of Pioglitazone.Withdrawn
ZiprasidoneThe metabolism of Pioglitazone can be decreased when combined with Ziprasidone.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Pioglitazone.Approved
Food Interactions
  • Take without regard to meals. Food slightly delays absorption rate but extent of absorption is not affected.
References
Synthesis Reference

Chandra Khanduri, Yatendra Kumar, Atulya Panda, Suchitra Chakraborty, Mukesh Sharma, "Process for the preparation of pioglitazone." U.S. Patent US20070078170, issued April 05, 2007.

US20070078170
General References
  1. Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA, Lund ET, Mathews WR: Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab. 2004 Feb;286(2):E252-60. Epub 2003 Oct 21. [PubMed:14570702 ]
  2. Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, Abresch EC, Capraro D, Murphy AN, Nechushtai R, Dixon JE, Jennings PA: MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone. Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14342-7. Epub 2007 Aug 31. [PubMed:17766440 ]
  3. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007 Sep 12;298(10):1180-8. [PubMed:17848652 ]
  4. Al-Majed A, Bakheit AH, Abdel Aziz HA, Alharbi H, Al-Jenoobi FI: Pioglitazone. Profiles Drug Subst Excip Relat Methodol. 2016;41:379-438. doi: 10.1016/bs.podrm.2015.11.002. Epub 2016 Feb 2. [PubMed:26940171 ]
  5. Janani C, Ranjitha Kumari BD: PPAR gamma gene--a review. Diabetes Metab Syndr. 2015 Jan-Mar;9(1):46-50. doi: 10.1016/j.dsx.2014.09.015. Epub 2014 Oct 13. [PubMed:25450819 ]
External Links
ATC CodesA10BD09 — Pioglitazone and alogliptinA10BD12 — Pioglitazone and sitagliptinA10BD05 — Metformin and pioglitazoneA10BD06 — Glimepiride and pioglitazoneA10BG03 — Pioglitazone
AHFS Codes
  • 68:20.28
PDB EntriesNot Available
FDA labelDownload (61.6 KB)
MSDSDownload (36.3 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceBMI >30 kg/m2 / Infertility, Female1
0CompletedBasic ScienceLung Inflammation1
0CompletedBasic SciencePeripheral Arterial Disease (PAD)1
0CompletedTreatmentPolycystic Ovaries Syndrome1
0Not Yet RecruitingBasic ScienceMetabolic Syndromes / Obese1
1Active Not RecruitingTreatmentProstatic Neoplasms, Castration-Resistant1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of ASP19411
1CompletedNot AvailableType 2 Diabetes Mellitus1
1CompletedBasic ScienceAmount of Pioglitazone in Blood / Drug-Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics / Pioglitazone / Rheumatoid Arthritis1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedPreventionDiabetes1
1CompletedSupportive CareAnaplastic Astrocytoma (AA) / Brain Neoplasms, Benign / Brain Neoplasms, Malignant / Glioblastoma Multiforme / Meningiomas malignant1
1CompletedTreatmentAdvanced Solid Tumors / Metastatic Solid Tumors1
1CompletedTreatmentAnemias1
1CompletedTreatmentBMI >27 kg/m2 / BMI >30 kg/m2 / Healthy Volunteers1
1CompletedTreatmentCastration Resistant Prostate Cancer (CRPC) / Pharmacokinetics of MDV31001
1CompletedTreatmentCrohn's Disease (CD)1
1CompletedTreatmentCystic Fibrosis (CF)1
1CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
1CompletedTreatmentHealthy Volunteers8
1CompletedTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD)1
1CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
1CompletedTreatmentType 2 Diabetes Mellitus3
1Not Yet RecruitingBasic ScienceAutoimmune Pulmonary Alveolar Proteinosis1
1Not Yet RecruitingHealth Services ResearchType 2 Diabetes Mellitus1
1RecruitingTreatmentInsulin Resistance / Rheumatoid Arthritis1
1TerminatedTreatmentOpioid-Related Disorders1
1Unknown StatusTreatmentMalignant Neoplasm of Pancreas1
1WithdrawnNot AvailableType 2 Diabetes Mellitus1
1, 2CompletedTreatmentAlcohol Use Disorder (AUD) / Cocaine Use Disorders1
1, 2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
1, 2CompletedTreatmentSevere Sepsis / Shock, Septic1
1, 2CompletedTreatmentType 2 Diabetes Mellitus1
1, 2Not Yet RecruitingTreatmentChronic Granulomatous Disease (CGD)1
1, 2RecruitingPreventionSystemic Lupus Erthematosus1
1, 2RecruitingTreatmentDisseminated Sclerosis1
1, 2RecruitingTreatmentLeukemia, Myeloid, Chronic-Phase1
1, 2TerminatedBasic ScienceHeroin Dependence / Nicotine Dependence1
1, 2Unknown StatusTreatmentMultiple Myeloma (MM)1
2Active Not RecruitingPreventionEndobronchial Dysplasia / Lung Cancers1
2CompletedDiagnosticDiabetes / Healthy Volunteers / Platelet Function1
2CompletedPreventionHead and Neck Carcinoma / Oral Leukoplakia1
2CompletedPreventionMild Cognitive Impairment (MCI)1
2CompletedTreatmentAirflow Obstruction / Airway Inflammation / Severe, Refractory Asthma1
2CompletedTreatmentAlzheimer's Disease (AD)1
2CompletedTreatmentAsthma Bronchial1
2CompletedTreatmentAutism Spectrum Disorder (ASD)1
2CompletedTreatmentBMI >30 kg/m21
2CompletedTreatmentCardiac Allograft Vasculopathy / Cardiac Transplant1
2CompletedTreatmentCardiovascular Disease (CVD)1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
2CompletedTreatmentCoronary Artery Disease / Oxidative Stress / Type 2 Diabetes Mellitus1
2CompletedTreatmentDiabetes Mellitus (DM)3
2CompletedTreatmentDiabetes Mellitus (DM) / Glucose Metabolism Disorders / Type 2 Diabetes Mellitus1
2CompletedTreatmentDiabetes Mellitus (DM) / Insulin Resistance1
2CompletedTreatmentESRD1
2CompletedTreatmentFatty Liver / Nonalcoholic Steatohepatitis1
2CompletedTreatmentHIV-1 and Hepatitis C Co-Infection1
2CompletedTreatmentHepatic Steatosis / Human Immunodeficiency Virus (HIV) Infections / Insulin Resistance1
2CompletedTreatmentHepatitis1
2CompletedTreatmentHypertensive / Inflammatory Reaction1
2CompletedTreatmentImpaired Glucose Tolerance (IGT) / Transplantation, Kidney1
2CompletedTreatmentInsulin Resistance / Metabolic Syndromes / Type 2 Diabetes Mellitus1
2CompletedTreatmentInsulin Resistance / Normal Stool Fat Levels / Pancreatitis, Chronic1
2CompletedTreatmentIntracerebral Hemorrhage1
2CompletedTreatmentLeukemia, Myeloid, Chronic-Phase1
2CompletedTreatmentMajor Depressive Disorder (MDD) / Metabolic Syndromes1
2CompletedTreatmentNonalcoholic Fatty Liver Disease1
2CompletedTreatmentOpioid Abuse1
2CompletedTreatmentParkinson's Disease (PD)1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentThyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene1
2CompletedTreatmentType 2 Diabetes Mellitus16
2Enrolling by InvitationPreventionSquamous Cell Carcinoma of the Skin1
2Not Yet RecruitingTreatmentAlcoholism1
2Not Yet RecruitingTreatmentChronic Myeloid Leukemia (CML)1
2Not Yet RecruitingTreatmentLeukemia, Myelogenous, Chronic, BCR-ABL Positive1
2RecruitingOtherChronic Myeloid Leukemia (CML)1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
2RecruitingTreatmentCancer of the Pancreas1
2RecruitingTreatmentChronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive1
2RecruitingTreatmentDiabetes Mellitus Type 2 With Hyperglycemia1
2RecruitingTreatmentHepatitis1
2RecruitingTreatmentNeoplasms, Oropharyngeal / Oral Cavity Neoplasm / Stage I Oral Cavity Squamous Cell Carcinoma / Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage I Oropharyngeal Squamous Cell Carcinoma / Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7 / Stage II Oral Cavity Squamous Cell Carcinoma / Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage II Oropharyngeal Squamous Cell Carcinoma / Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7 / Stage III Oral Cavity Squamous Cell Carcinoma / Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Oral Cavity Squamous Cell Carcinoma / Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVC Oral Cavity Squamous Cell Carcinoma / Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v71
2RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Non-squamous Cell Lung Cancer / Squamous Cell Carcinoma of Lung1
2RecruitingTreatmentPolycystic Kidney Diseases1
2RecruitingTreatmentPressure Ulcers / Spinal Cord Injuries (SCI)1
2TerminatedNot AvailableType 2 Diabetes Mellitus1
2TerminatedTreatmentAlcohol Dependence / Alcohol Drinking / Alcohol-Related Disorders / Stress1
2TerminatedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2TerminatedTreatmentAsthma Bronchial / BMI >30 kg/m21
2TerminatedTreatmentChronic Kidney Disease (CKD)1
2TerminatedTreatmentDiabetes Mellitus (DM)1
2TerminatedTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
2TerminatedTreatmentNonalcoholic Steatohapatitis1
2TerminatedTreatmentOral Leukoplakia1
2TerminatedTreatmentStage IA Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer1
2TerminatedTreatmentStrokes1
2TerminatedTreatmentType 2 Diabetes Mellitus2
2Unknown StatusNot AvailableChronic Hepatitis C Infection1
2Unknown StatusTreatmentPsoriasis1
2WithdrawnTreatmentAirflow Obstruction / Airway Hyperactivity / Airway Inflammation / Asthma Bronchial1
2, 3CompletedTreatmentArterial Occlusive Diseases / Insulin Resistance / Intermittent Claudication1
2, 3CompletedTreatmentCoronary Artery Disease / Type 2 Diabetes Mellitus1
2, 3CompletedTreatmentMajor Depressive Disorder (MDD)1
2, 3CompletedTreatmentType 2 Diabetes Mellitus4
2, 3CompletedTreatmentMinor burns1
2, 3WithdrawnDiagnosticEndometriosis1
3Active Not RecruitingTreatmentMild Cognitive Impairment Due to Alzheimer's Disease1
3CompletedBasic ScienceType 2 Diabetes Mellitus1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedPreventionImpaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus1
3CompletedTreatmentDiabetes1
3CompletedTreatmentDiabetes Mellitus (DM)12
3CompletedTreatmentDiabetes Mellitus (DM) / Dyslipidemias1
3CompletedTreatmentDiabetes Mellitus (DM) / Proteinuria / Transplantation, Kidney1
3CompletedTreatmentDiabetes / Myocardial Infarction (MI) / Strokes1
3CompletedTreatmentDiabetes / Type 2 Diabetes Mellitus2
3CompletedTreatmentFriedreich's Ataxia1
3CompletedTreatmentHypertensive / Type 2 Diabetes Mellitus1
3CompletedTreatmentLiver Diseases1
3CompletedTreatmentRheumatoid Arthritis1
3CompletedTreatmentType 2 Diabetes Mellitus36
3RecruitingTreatmentMild Cognitive Impairment Due to Alzheimer's Disease1
3RecruitingTreatmentType 2 Diabetes Mellitus1
3TerminatedTreatmentChronic Hepatitis C Virus (HCV) Infection / Insulin Resistance1
3TerminatedTreatmentDiabetes Mellitus (DM)1
3TerminatedTreatmentDiabetes / Type 2 Diabetes Mellitus1
3TerminatedTreatmentHIV-Associated Lipodystrophy Syndrome / Human Immunodeficiency Virus (HIV) Infections1
3TerminatedTreatmentType 2 Diabetes Mellitus4
3Unknown StatusTreatmentCoronary Artery Atherosclerosis / Coronary Artery Restenosis / Diabetes1
3Unknown StatusTreatmentFatty Liver1
3Unknown StatusTreatmentMetabolic Syndromes1
4CompletedNot AvailableDiabetes Mellitus (DM)1
4CompletedNot AvailableDiabetic Nephropathies / Dyslipidemias / Hypertensive / Type 2 Diabetes Mellitus1
4CompletedNot AvailableType 2 Diabetes Mellitus1
4CompletedBasic ScienceDiabetes1
4CompletedBasic ScienceDiabetes / Glucose Metabolism Disorders1
4CompletedBasic ScienceInsulin Resistance / Metabolic Syndromes / Pre-Diabetic1
4CompletedBasic ScienceType 2 Diabetes Mellitus2
4CompletedPreventionAdverse Effects / Coronary Artery Atherosclerosis / Insulin resistance syndrome1
4CompletedPreventionAngina Pectoris / Coronary Artery Disease / Percutaneous Coronary Intervention (PCI) / Type 2 Diabetes Mellitus1
4CompletedPreventionDiabetes1
4CompletedTreatmentAscites / Liver Cirrhosis / Portal Hypertension1
4CompletedTreatmentBMI >30 kg/m2 / Overweight With Indications for Weight Loss1
4CompletedTreatmentBone Metabolism1
4CompletedTreatmentCardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1
4CompletedTreatmentChronic Hepatitis C Infection1
4CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
4CompletedTreatmentCoronary Artery Stenosis / Diabetes Mellitus (DM)1
4CompletedTreatmentCoronary Heart Disease (CHD) / Type 2 Diabetes Mellitus1
4CompletedTreatmentDepression, Bipolar / Insulin Resistance / Metabolic Syndromes1
4CompletedTreatmentDiabetes Mellitus (DM)4
4CompletedTreatmentDiabetes Mellitus (DM) / Livers1
4CompletedTreatmentDiabetes / Hypertensive1
4CompletedTreatmentDiabetic Stable Angina / Diabetic Unstable Angina1
4CompletedTreatmentEnd-Stage Renal Disease (ESRD)1
4CompletedTreatmentHealthy Volunteers / Impaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus1
4CompletedTreatmentHepatitis C, Chronic1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
4CompletedTreatmentHypertensive / Insulin Resistance1
4CompletedTreatmentInflammatory Reaction1
4CompletedTreatmentInsulin Resistance / Polycystic Ovaries Syndrome1
4CompletedTreatmentInsulin Resistance / Type 2 Diabetes Mellitus2
4CompletedTreatmentMetabolic Syndromes2
4CompletedTreatmentNonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis / Type 2 Diabetes Mellitus1
4CompletedTreatmentNonalcoholic Steatohepatitis2
4CompletedTreatmentPolycystic Ovaries Syndrome1
4CompletedTreatmentSecondary Drug Failure / Type 2 Diabetes Mellitus1
4CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
4CompletedTreatmentType 2 Diabetes Mellitus13
4CompletedTreatmentType 2 Diabetes Mellitus / Vascular Diseases1
4Enrolling by InvitationTreatmentType 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentBone destruction / Diabetes Mellitus (DM)1
4RecruitingTreatmentAtaxia-Telangiectasia1
4RecruitingTreatmentNonalcoholic Fatty Liver / Type 2 Diabetes Mellitus1
4RecruitingTreatmentType 2 Diabetes Mellitus8
4TerminatedTreatmentBipolar Disorder (BD) / Insulin Resistance1
4TerminatedTreatmentChronic Hepatitis C Infection / Fatty Liver / HIV Disease / Liver Diseases / Steatosis1
4TerminatedTreatmentObstructive Sleep Apnea (OSA) / Polycystic Ovaries Syndrome1
4TerminatedTreatmentPulmonary Hypertension (PH)1
4TerminatedTreatmentType 2 Diabetes Mellitus2
4Unknown StatusBasic ScienceType 2 Diabetes Mellitus1
4Unknown StatusTreatmentChronic Hepatitis C Virus (HCV) Infection1
4Unknown StatusTreatmentCoronary Artery Atherosclerosis / Coronary Heart Disease (CHD) / Inflammatory Reaction1
4Unknown StatusTreatmentDiabetes1
4Unknown StatusTreatmentDiabetes Mellitus (DM) / Oxidative Stress1
4Unknown StatusTreatmentESRD1
4Unknown StatusTreatmentInsulin Resistance / Major Depressive Disorder (MDD)1
4Unknown StatusTreatmentType 2 Diabetes Mellitus2
4WithdrawnTreatmentBMI >30 kg/m2 / Insulin Resistance1
4WithdrawnTreatmentGlucose Metabolism Disorders1
4WithdrawnTreatmentType 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableAdipocytes / Adiponectin / Bone Density / Mesenchymal Stem Cells / Osteoblast / Osteocalcin1
Not AvailableCompletedNot AvailableBladder Cancers / Diabetes1
Not AvailableCompletedNot AvailableChronic Hepatitis C Virus (HCV) Infection1
Not AvailableCompletedNot AvailableCongenital Adrenal Hyperplasia (CAH)1
Not AvailableCompletedNot AvailableDiabetes Mellitus, Type 2, Cancer1
Not AvailableCompletedNot AvailableKetoacidosis, Diabetic / Ketosis Prone Diabetes / Severe Hyperglycemia1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus10
Not AvailableCompletedBasic ScienceBMI >30 kg/m2 / Insulin Resistance1
Not AvailableCompletedBasic ScienceBMI >30 kg/m2 / Metabolic Syndromes1
Not AvailableCompletedBasic ScienceBMI >30 kg/m2 / Sarcopenia1
Not AvailableCompletedBasic ScienceMetabolic Syndromes / Prediabetic State1
Not AvailableCompletedBasic ScienceRheumatoid Arthritis1
Not AvailableCompletedBasic ScienceType 2 Diabetes Mellitus4
Not AvailableCompletedDiagnosticCardiovascular Disease (CVD) / HIV Lipodystrophy / Human Immunodeficiency Virus (HIV) Infections / Insulin Resistance / The Metabolic Syndrome1
Not AvailableCompletedPreventionAtherosclerosis / Insulin Resistance / Transplantation, Kidney1
Not AvailableCompletedTreatmentAids / BMI >30 kg/m2 / Cardiovascular Disease (CVD) / HIV Disease / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentAtherosclerosis / Impaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentCognitive Impairments / Diabetes / Insulin Resistance / Schizophrenic Disorders1
Not AvailableCompletedTreatmentCystic Fibrosis (CF)1
Not AvailableCompletedTreatmentDiabetes / Endstage Renal Disease1
Not AvailableCompletedTreatmentDiabetic Nephropathies / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentEnd Stage Renal Disease (ESRD) / Hemodialysis-dependent patients1
Not AvailableCompletedTreatmentGrowth Hormone Deficiency (GHD)1
Not AvailableCompletedTreatmentHypertriglyceridemias / Inflammatory Reaction / Insulin Resistance / Peritoneal dialysis therapy / Pioglitazone1
Not AvailableCompletedTreatmentNewly Diagnosed / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus3
Not AvailableEnrolling by InvitationBasic ScienceType 2 Diabetes Mellitus1
Not AvailableRecruitingNot AvailableBladder Cancers1
Not AvailableRecruitingBasic ScienceUric Acid Kidney Stone Disease1
Not AvailableRecruitingOtherType 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentImpaired Fasting Glucose (IFG) / Impaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentType 2 Diabetes Mellitus1
Not AvailableTerminatedNot AvailableDiabetes / Hypogonadism / Inflammatory Reaction / Metabolic Syndromes1
Not AvailableTerminatedBasic ScienceFatty Liver1
Not AvailableTerminatedHealth Services ResearchPolycystic Ovaries Syndrome1
Not AvailableTerminatedPreventionPrediabetic State1
Not AvailableTerminatedTreatmentChronic Kidney Disease (CKD)1
Not AvailableTerminatedTreatmentType 2 Diabetes Mellitus1
Not AvailableUnknown StatusNot AvailableAnti Inflammatory Non-Steroidal / Cystic Fibrosis (CF) / Neutrophils1
Not AvailableUnknown StatusNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableUnknown StatusNot AvailableInsulin Sensitivity / Obstructive Sleep Apnea (OSA)1
Not AvailableUnknown StatusBasic ScienceBMI >30 kg/m2 / Cardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1
Not AvailableUnknown StatusBasic SciencePolycystic Ovaries Syndrome1
Not AvailableUnknown StatusPreventionDiabetes Mellitus (DM) / Myocardial Infarction (MI)1
Not AvailableUnknown StatusTreatmentMetabolic Parameters and Liver Histology1
Not AvailableWithdrawnTreatmentModerate, refractory Atopic dermatitis1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, film coated, extended releaseOral
TabletOcclusive dressing technique15 mg/1
TabletOcclusive dressing technique30 mg/1
TabletOral15 mg
TabletOral30 mg
TabletOral45 mg
TabletOral
TabletOral15 mg/1
TabletOral30 mg/1
TabletOral45 mg/1
Tablet, film coatedOral
Prices
Unit descriptionCostUnit
Actos 30 mg tablet12.48USD tablet
Actos 45 mg tablet11.22USD tablet
Actos 15 mg tablet6.3USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4687777 No1994-01-172011-01-17Us
CA2179584 No2007-04-242016-06-20Canada
CA2531834 No2006-12-052016-06-20Canada
US6150383 No1996-06-192016-06-19Us
US6211205 No1996-06-192016-06-19Us
US6303640 No1996-08-092016-08-09Us
US6329404 No1996-06-192016-06-19Us
US8071130 No2008-06-082028-06-08Us
US7538125 No1996-06-192016-06-19Us
US7700128 No2007-01-302027-01-30Us
US5965584 No1996-06-192016-06-19Us
US6166042 No1996-06-192016-06-19Us
US6166043 No1996-06-192016-06-19Us
US6172090 No1996-06-192016-06-19Us
US6790459 No2001-03-172021-03-17Us
US7919116 No1998-03-202018-03-20Us
US8475841 No1998-03-202018-03-20Us
US6099859 No1998-03-202018-03-20Us
US6866866 No2001-03-172021-03-17Us
US7785627 No2006-07-312026-07-31Us
US7959946 No2006-07-312026-07-31Us
US8470368 No2003-09-192023-09-19Us
US8668931 No2003-09-192023-09-19Us
US9060941 No2003-09-192023-09-19Us
US6495162 No1998-03-202018-03-20Us
US6150384 No1996-06-192016-06-19Us
US6271243 No1996-06-192016-06-19Us
US9101660 No2007-01-222027-01-22Us
US6303661 No1997-04-242017-04-24Us
US6890898 No1999-02-022019-02-02Us
US7078381 No1999-02-022019-02-02Us
US7459428 No1999-02-022019-02-02Us
US7807689 No2008-06-272028-06-27Us
US8173663 No2005-03-152025-03-15Us
US8288539 No2005-03-152025-03-15Us
US8637079 No2009-06-042029-06-04Us
US9320714 No2009-02-032029-02-03Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)183-184 °CNot Available
water solubilitymg/mLNot Available
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00442 mg/mLALOGPS
logP3.17ALOGPS
logP3.33ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)6.66ChemAxon
pKa (Strongest Basic)5.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area68.29 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity97.39 m3·mol-1ChemAxon
Polarizability37.91 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier+0.8753
Caco-2 permeable-0.5659
P-glycoprotein substrateNon-substrate0.6358
P-glycoprotein inhibitor INon-inhibitor0.5708
P-glycoprotein inhibitor IINon-inhibitor0.9673
Renal organic cation transporterNon-inhibitor0.6018
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5267
CYP450 1A2 substrateInhibitor0.8384
CYP450 2C9 inhibitorInhibitor0.6353
CYP450 2D6 inhibitorNon-inhibitor0.8085
CYP450 2C19 inhibitorInhibitor0.6967
CYP450 3A4 inhibitorNon-inhibitor0.6035
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8864
Ames testNon AMES toxic0.7303
CarcinogenicityNon-carcinogens0.9171
BiodegradationNot ready biodegradable0.7884
Rat acute toxicity2.0115 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9341
hERG inhibition (predictor II)Non-inhibitor0.8498
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0a4i-0009000000-070cf69939743719671dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0bt9-0209000000-d9d34be41f49a9ffbdefView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0udi-0900000000-ef25b6f93ae4fcee23c3View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0udi-0900000000-3011f00e839bfc06d89dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0gba-0900000000-b0488e0d155d1587bbb5View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-014j-0900000000-b32570ad6af58a4a6c72View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , negativesplash10-0a4i-0009000000-c67370f6cb2ad36cab3eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF , positivesplash10-0a59-0908000000-aab2ee9addb1334a7064View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0a4i-0009000000-fd4bc4d9d4bb45e91295View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0a4i-0409000000-115c6889c4e9205b3028View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-001i-0900000000-a2e878da4d2f6a4bb717View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-001i-0900000000-031fa259cd3b26217dadView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-00lr-0900000000-e2cd3c294a2e53e1a17eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0159-1900000000-aacbd8dce006b5ef5938View in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-0a4i-1619000000-4b248e31af7f50e87108View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-053r-0906000000-a73152b364036b45dfebView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassPhenol ethers
Sub ClassNot Available
Direct ParentPhenol ethers
Alternative ParentsPhenoxy compounds / Thiazolidinediones / Alkyl aryl ethers / Pyridines and derivatives / Heteroaromatic compounds / Dicarboximides / Thiocarbamic acid derivatives / Organic carbonic acids and derivatives / Azacyclic compounds / Organopnictogen compounds
SubstituentsPhenoxy compound / Phenol ether / Alkyl aryl ether / Thiazolidinedione / Monocyclic benzene moiety / Pyridine / Dicarboximide / Heteroaromatic compound / Thiazolidine / Carbonic acid derivative
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptorsaromatic ether, pyridines, thiazolidenediones (CHEBI:8228 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation...
Gene Name:
PPARG
Uniprot ID:
P37231
Uniprot Name:
Peroxisome proliferator-activated receptor gamma
Molecular Weight:
57619.58 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Sugii S, Olson P, Sears DD, Saberi M, Atkins AR, Barish GD, Hong SH, Castro GL, Yin YQ, Nelson MC, Hsiao G, Greaves DR, Downes M, Yu RT, Olefsky JM, Evans RM: PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization. Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22504-9. doi: 10.1073/pnas.0912487106. Epub 2009 Dec 16. [PubMed:20018750 ]
  3. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA: Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9. [PubMed:15356026 ]
  4. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995 Jun 2;270(22):12953-6. [PubMed:7768881 ]
  5. Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998 Apr;47(4):507-14. [PubMed:9568680 ]
  6. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996 Feb 2;39(3):665-8. [PubMed:8576907 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-linoleic acid and eicosapentanoic acid. Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as ...
Gene Name:
PPARD
Uniprot ID:
Q03181
Uniprot Name:
Peroxisome proliferator-activated receptor delta
Molecular Weight:
49902.99 Da
References
  1. Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, Katayama S: Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun. 2002 Jan 11;290(1):131-9. [PubMed:11779144 ]
  2. Sarath Josh MK, Pradeep S, Vijayalekshmi Amma KS, Balachandran S, Abdul Jaleel UC, Doble M, Spener F, Benjamin S: Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor alpha, beta, gamma subtypes: an in silico approach. J Appl Toxicol. 2014 Jul;34(7):754-65. doi: 10.1002/jat.2902. Epub 2013 Jul 11. [PubMed:23843199 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fa...
Gene Name:
PPARA
Uniprot ID:
Q07869
Uniprot Name:
Peroxisome proliferator-activated receptor alpha
Molecular Weight:
52224.595 Da
References
  1. Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, Katayama S: Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun. 2002 Jan 11;290(1):131-9. [PubMed:11779144 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Uniprot Name:
Amine oxidase [flavin-containing] B
Molecular Weight:
58762.475 Da
References
  1. Binda C, Aldeco M, Geldenhuys WJ, Tortorici M, Mattevi A, Edmondson DE: Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs. ACS Med Chem Lett. 2011 Oct 15;3(1):39-42. [PubMed:22282722 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Uniprot Name:
Cytochrome P450 2C8
Molecular Weight:
55824.275 Da
References
  1. Muschler E, Lal J, Jetter A, Rattay A, Zanger U, Zadoyan G, Fuhr U, Kirchheiner J: The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. Basic Clin Pharmacol Toxicol. 2009 Dec;105(6):374-9. doi: 10.1111/j.1742-7843.2009.00457.x. Epub 2009 Jul 15. [PubMed:19614891 ]
  2. Jaakkola T, Laitila J, Neuvonen PJ, Backman JT: Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51. [PubMed:16867170 ]
  3. Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW: Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46. [PubMed:12642470 ]
  4. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Jaakkola T, Laitila J, Neuvonen PJ, Backman JT: Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51. [PubMed:16867170 ]
  2. Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW: Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46. [PubMed:12642470 ]
  3. Nowak SN, Edwards DJ, Clarke A, Anderson GD, Jaber LA: Pioglitazone: effect on CYP3A4 activity. J Clin Pharmacol. 2002 Dec;42(12):1299-302. [PubMed:12463723 ]
  4. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Uniprot Name:
Prostaglandin G/H synthase 1
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Uniprot Name:
Cytochrome P450 2C19
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Uniprot Name:
Cytochrome P450 2C9
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Uniprot Name:
Cytochrome P450 2D6
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Uniprot Name:
Solute carrier organic anion transporter family member 1B3
Molecular Weight:
77402.175 Da
References
  1. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, Tamai I: Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos. 2004 Mar;32(3):291-4. [PubMed:14977862 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Uniprot Name:
Solute carrier organic anion transporter family member 1B1
Molecular Weight:
76447.99 Da
References
  1. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, Tamai I: Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos. 2004 Mar;32(3):291-4. [PubMed:14977862 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:36